NDUFA9

Across TCGA pan-cancer cohorts, NDUFA9 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NDUFA9 data layer compared with 19 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NDUFA9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NDUFA9 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, PDAC, and COAD are the cancer types where NDUFA9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	0.904	0.607	.004	16	view →
PDAC	DFS	Quartile	II,III,IV	0.603	0.890	.005	12	view →
COAD	DFS	Median	III,IV	0.897	1.000	.044	6	view →
LUAD	OS	Tertile	II,III,IV	0.861	1.000	.016	6	view →
GBM	OS	Median	All	0.917	0.717	.001	3	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.529	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NDUFA9–CCRCC (OS)

Open the CCRCC breakdown →